t
Futura Medical plc announced on 19 August 2024 that it will release its unaudited results for the six months ended 30 June 2024 on 10 September 2024. On the same date, the Company will host a webinar for retail investors at 9:00am BST and a separate webinar for analysts at 11:00am BST.
| Date | 19 Aug 2024 |
| Time | 07:00:14 |
| Category | Results |
| ID | 8171A |
19 August 2024
Futura Medical plc
("Futura" or the "Company")
Notice of Results
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, will announce its unaudited results for the six months ended 30 June 2024 on Tuesday 10 September 2024.
The Company will be hosting a webinar for retail investors via the Investor Meet Company platform on 10 September 2024, at 9:00am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9:00am BST the day before, or at any time during the live presentation.
Investors can register for the presentation via the following link: https://www.investormeetcompany.com/futura-medical-plc/register-investor
In addition, management will be hosting a webinar for analysts on 10 September 2024 at 11:00am BST. If you would like to register, please contact [email protected]
Contacts:
|
Futura Medical plc
|
James Barder Chief Executive Officer Angela Hildreth Finance Director and COO
|
+44 (0)1483 685 670
|
|
Panmure Liberum Nominated Adviser and Broker
|
Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) |
+44 (0)20 3100 2000
|
|
|
|
|
|
Stifel Nicolaus Europe Limited Joint Broker
|
Alan Selby Ben Maddison
|
+44 (0)207 710 7600
|
|
|
|
|
|
Alma Strategic Communications |
Rebecca Sanders-Hewett Sam Modlin Will Ellis Hancock |
+44 (0)20 3405 0205 |
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.
Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.
ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.
Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.